GE HealthCare has announced FDA clearance for its Centiloid scaling tool, designed to quantify amyloid plaque density in patients potentially suffering from Alzheimer's disease. Integrated with MIMneuro, a vendor-neutral solution, the tool supports clinicians in evaluating Alzheimer’s by providing a standardized metric for amyloid imaging using PET scans. This development aims to increase diagnostic confidence and enhance treatment access.
The Centiloid scale tool arrives as pharmaceutical companies launch new amyloid-targeting therapies, such as Eli Lilly’s Kisunla and Biogen’s Lequembi, to combat Alzheimer’s. The tool will complement existing GE HealthCare solutions, including PET and MR scanners and amyloid PET tracers, by improving amyloid status determination and overall care pathways.
GE HealthCare’s initiative is part of a broader effort to advance personalized Alzheimer’s care, driven by the growing need for accurate, timely diagnosis as new treatments become available. The goal is to offer more patients access to innovative, cutting-edge care options that target the underlying disease mechanisms.
Click here to read the original news story.